Orforglipron

Orforglipron is a first-in-class oral small-molecule GLP-1 receptor agonist with robust Phase 3 clinical evidence.

How It Works (Simplified)

Orforglipron achieves similar metabolic effects to injectable GLP-1 drugs, but in a convenient oral pill:

Key Research: Sloop KW et al. (Sci Transl Med 2024) characterized the pharmacological basis for non-peptide GLP-1R agonism by orforglipron, showing high-affinity, selective receptor binding with negligible beta-arrestin recruitment. PMID:39693407

Phase 3 Results & FDA Review (2025-2026)

ATTAIN Clinical Program: The Phase 3 ATTAIN (obesity; ATTAIN-1, ATTAIN-2) and ACHIEVE (type 2 diabetes; ACHIEVE-2, ACHIEVE-3, ACHIEVE-5) programs demonstrated clinically significant weight loss and glycemic improvement with orforglipron, a first-in-class oral non-peptide GLP-1 receptor agonist.

Head-to-Head Data: A head-to-head comparison with oral semaglutide published in The Lancet (February 2026) provided direct comparative efficacy data, positioning orforglipron competitively in the oral GLP-1 landscape.

ACHIEVE-2 — against an oral SGLT2 inhibitor: ACHIEVE-2, published in The Lancet on 8 June 2026, randomised 962 adults with type 2 diabetes inadequately controlled on metformin to one of three orforglipron strengths or dapagliflozin 10 mg, across 73 sites in six countries for 40 weeks (PMID:42259339, NCT06192108). The primary analysis used the treatment-regimen estimand, which the paper names as primary with the efficacy estimand considered supportive. From a mean baseline HbA1c of 8.14%, HbA1c fell 1.23%, 1.50% and 1.56% across the ascending orforglipron strengths against 0.81% with dapagliflozin; every strength was non-inferior against the prespecified 0.3% margin, with estimated differences of -0.42% (95% CI -0.62 to -0.23), -0.70% (-0.90 to -0.49) and -0.75% (-0.96 to -0.55). The trade-off appears in tolerability: mild-to-moderate gastrointestinal events affected 46 to 54% of orforglipron participants against 12% of the dapagliflozin group. The trial was open-label between the two drugs, with orforglipron strength blinded.

ACHIEVE-5 — added to basal insulin: ACHIEVE-5, published in JAMA on 4 August 2026, tested orforglipron alongside titrated insulin glargine in 546 adults at 72 sites across five countries (PMID:42251769, NCT06109311). This was a long-standing-diabetes population — median duration 14.6 years, mean baseline HbA1c 8.50%. At week 40, HbA1c fell 1.58%, 1.88% and 1.82% across the three strengths against 0.79% with placebo, and mean body weight fell 2.6%, 4.8% and 5.4% against a 0.2% gain on placebo. Clinically significant hypoglycaemia was not increased against placebo, which matters in a population already on insulin.

ACHIEVE-J — open-label Phase 3 safety, not a weight-loss headline: ACHIEVE-J (PMID:42607698, NCT06010004) randomised 401 Japanese adults with type 2 diabetes (n=132 / 135 / 134 across three strengths) for 52 weeks. The primary endpoint was safety, not efficacy. 339 participants (85%) had at least one treatment-emergent adverse event (81%, 84% and 88% across strengths). Discontinuations due to an adverse event were 5%, 8% and 14%. Gastrointestinal symptoms were the most common events leading to discontinuation. Level 2 hypoglycaemia occurred in 2% of two of the three groups; no level 3 events. The abstract does not report a treatment-regimen HbA1c or weight-change figure, so none is stated here. This is not a weight-loss headline and does not change the Foundayo chronic-weight-management indication versus unapproved type 2 diabetes use, nor is it a head-to-head against semaglutide.

Hepatic safety across the phase 3 programme: A pooled analysis of seven phase 3 trials covering 11,220 participants, published in June 2026, examined liver signals over up to 104 weeks (PMID:42338042). Orforglipron was associated with mean reductions in ALT and AST. Six orforglipron participants (0.1%) and six comparator participants (0.1%) met the aminotransferase and bilirubin thresholds that trigger a Hy’s Law review; alternative causes accounted for all of the orforglipron cases, and none met drug-induced liver injury criteria. Hepatic adverse events were balanced against pooled comparators. The trials excluded people whose baseline aminotransferases were already substantially elevated, so this analysis speaks to a population screened for liver health.

ATTAIN-1 registry results and the two estimands: ClinicalTrials.gov posted the ATTAIN-1 results on 14 August 2026 (NCT05869903). The posted primary outcome — a mean body-weight change of -12.35% at the highest strength against -0.87% on placebo — is calculated on data collected only up to study-drug discontinuation, which is the efficacy estimand. The published NEJM figure of 11.2% against 2.1% is the treatment-regimen estimand, which keeps every randomised participant in the analysis. Both come from the same trial and both are correct; this page leads with the published treatment-regimen figure, and the registry number is the one that has circulated as “12.4%”.

Older adults: A post hoc subgroup analysis pooled the 616 participants aged 65 or over from ATTAIN-1 and ATTAIN-2 (PMID:42577069). Week-72 weight change ran from -7.9% to -13.0% across strengths in ATTAIN-1 and from -7.5% to -12.2% in ATTAIN-2, against -1.6% and -2.3% on placebo. Results were comparable to participants under 65. This is a post hoc analysis, so it generates a reasonable expectation rather than a tested one.

US regulatory status: The FDA approved orforglipron on 1 April 2026 under NDA 220934, marketed as Foundayo. The indication is chronic weight management — reducing excess body weight and maintaining weight reduction long term in adults with obesity, or in adults with overweight who have at least one weight-related comorbid condition — in combination with a reduced-calorie diet and increased physical activity. The FDA’s July 2026 revised prescribing label advises against concomitant use with another GLP-1 receptor agonist; this is a limitation of use, not a formal contraindication. The label’s contraindications concern personal or family history of medullary thyroid carcinoma, MEN 2, and serious hypersensitivity. It also identifies interactions with strong CYP3A4 inhibitors and inducers, simvastatin, and possible absorption effects for other oral medicines. Orforglipron is not FDA-approved for type 2 diabetes. Approval in other jurisdictions was not established in this review.

Important Limitations

• Long-term cardiovascular outcomes data still pending (ACHIEVE-CVOT ongoing)
• Approved only for chronic weight management; type 2 diabetes remains an unapproved use, despite the ACHIEVE-2 and ACHIEVE-5 phase 3 results. ACHIEVE-J is an open-label safety trial, not an efficacy readout
• The revised US FDA label is available, but this review did not compare every line with the original April 2026 label
• The two weight-loss figures reported for ATTAIN-1, 11.2% and 12.35%, are the same result under two estimands and should not be quoted side by side as though they were separate findings
• Gastrointestinal adverse-event rates vary by trial and comparator; ACHIEVE-2 reported gastrointestinal events in 46–54% of orforglipron groups versus 12% with dapagliflozin
• Daily oral tablet (unlike weekly injectable alternatives)
• The approved indication is adjunctive to a reduced-calorie diet and increased physical activity